New hope for rare thymus cancers: immune therapy trial
NCT ID NCT03076554
Summary
This study is testing whether the immunotherapy drug avelumab is safe and can help control thymoma or thymic carcinoma that has returned or worsened after standard platinum-based chemotherapy. It involves 56 adults who will receive avelumab by IV infusion every two weeks until side effects become intolerable or the cancer progresses. The main goals are to see if the treatment shrinks tumors and to monitor its safety profile.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYMOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.